CDK7 and non-small cell lung carcinoma: More targeted approaches could be considered to specifically target cycling cells at the DTP stage, as shown in NSCLC cell lines treated with EGFR-TKI and THZ1, a CDK7/12 inhibitor, which efficiently increases cell death and prevents relapse in vitro [123].